congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Oral
Dato-DXd
WCLC 2024 | September 7-10, 2024
Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01
Poster
I-DXd
WCLC 2024 | September 7-10, 2024
Exposure–response analyses to support phase 3 dose selection for ifinatamab deruxtecan (I-DXd) in patients with ES-SCLC
Oral
I-DXd
WCLC 2024 | September 7-10, 2024
Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis of IDeate-Lung01
Oral
T-DXd
WCLC 2024 | September 7-10, 2024
Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1
Poster
Dato-DXd, Valemetostat, Other/Multi
WCLC 2024 | September 7-10, 2024
Valemetostat and datopotamab deruxtecan in previously treated, advanced, unresectable, or metastatic nonsquamous NSCLC